Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, MD; Kendra L. Sweet, MD; Anthony S. Stein, MD; Eunice S. Wang, MD; David A. Rizzieri, MD; Sumithira Vasu, MD, MBBS; Todd L. Rosenblat, MD; Christopher L. Brooks, PhD; Nassir Haboubi, PhD; Tariq I. Mughal, MD; Hagop Kantarjian, MD; Marina Konopleva, MD, PhD; and Andrew A. Lane, MD, PhD

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy. We report long-term results, including data from the continued access phase, of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp (TAG) in adults with treatment-naive and relapsed/refractory BPDCN. The primary outcome was complete response (CR) + clinical CR (CRc: CR with residual skin abnormality not indicative of active disease). Eighty-four (65 treatment-naive and 19 relapsed/refractory) of 89 patients received TAG 12 μg/kg once daily; the median follow-up was 34.0 months. For treatment-naive patients, the overall response rate was 75%; 57% achieved CR + CRc. The median time to remission was 39 (range, 14-131) days, and the median CR + CRc duration was 24.9 (95% CI, 3.8 to not reached) months. Nineteen patients (51%) with CR + CRc were bridged to stem-cell transplant, with a median CR + CRc duration of 22.2 (range, 1.5-57.4) months. Most common adverse events were increased alanine (64%) or aspartate (60%) aminotransferase and hypoalbuminemia (51%); most occurred in cycle 1 and were transient. Capillary leak syndrome occurred in 21% of patients (grade 3: 7%). In first-line patients with BPDCN, TAG monotherapy resulted in high and durable responses, allowing many to bridge to stem-cell transplant. TAG was generally well-tolerated with a predictable and manageable safety profile.

J Clin Oncol 40:3032-3036. © 2022 by American Society of Clinical Oncology

Introduction

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, rare myeloid malignancy of the dendritic cell lineage that carries a poor prognosis. Diagnosis is based on distinct morphology and expression of cell surface markers, in particular, CD123 (interleukin 3 receptor alpha).1,2 Historic treatment with combination leukemia or lymphoma chemotherapy regimens often resulted in nondurable responses with high rates of relapse.1,3-6 Bridging to stem-cell transplant (SCT) is the ultimate therapeutic goal but is often not adequately achieved with induction chemotherapy regimens.

Tagraxofusp (TAG; SL-401) is a first-in-class CD123-targeted therapy comprising human interleukin-3 fused to a truncated diphtheria toxin payload.7-11 TAG has been approved by the US Food and Drug Administration for the treatment of patients with BPDCN age ≥ 2 years12,13 and by the European Medicines Agency for adult patients with newly diagnosed BPDCN.14

We report longer-term (median time: 34.0 months) data from the 0114 study (ClinicalTrials.gov identifier: NCT02113982), comprising patients from the primary analysis of the pivotal trial plus those enrolled into the continued access cohort.

Methods

The trial design, efficacy and safety assessments, and statistical analysis have been previously published.15 This multicenter study evaluating TAG monotherapy in adults with treatment-naive (first-line [1L]) or relapsed/refractory (R/R) BPDCN comprised four stages: dose escalation (stage 1), expansion (stage 2), pivotal and confirmatory (stage 3), and continued access (stage 4; Data Supplement, online only). TAG was administered as a daily intravenous infusion on days 1-5 of each...
### TABLE 1. Baseline Characteristics of Patients Treated Once Daily With Tagraxofusp 12 μg/kg

| Parameter                              | 1L BPDCN (n = 65) | R/R BPDCN (n = 19) |
|----------------------------------------|-------------------|--------------------|
| **Sex, No. (%)**                       |                   |                    |
| Male                                   | 52 (80)           | 16 (84)            |
| Female                                 | 13 (20)           | 3 (16)             |
| **Race, No. (%)**                      |                   |                    |
| White                                  | 57 (88)           | 17 (90)            |
| Others                                 | 8 (12)            | 2 (11)             |
| **Age, years, median (range [minimum-maximum])** | 68 (22-84)       | 72 (44-87)         |
| **ECOG, No. (%)**                      |                   |                    |
| 0                                      | 31 (48)           | 7 (37)             |
| 1                                      | 31 (48)           | 12 (63)            |
| 2                                      | 2 (3)             | 0                  |
| **BPDCN at baseline, No. (%)**         |                   |                    |
| Skin                                   | 60 (92)           | 15 (79)            |
| BM                                     | 32 (49)           | 12 (63)            |
| Peripheral blood                       | 17 (26)           | 1 (5)              |
| Lymph nodes                            | 33 (51)           | 9 (47)             |
| Visceral                               | 9 (14)            | 4 (21)             |
| **Prior therapies, No. (%)**           |                   |                    |
| 1                                      | —                 | 11 (58)            |
| 2                                      | —                 | 3 (16)             |
| 3                                      | —                 | 2 (11)             |
| ≥ 4                                    | —                 | 2 (11)             |

Abbreviations: 1L, first-line; BM, bone marrow; BPDCN, blastic plasmacytoid dendritic cell neoplasm; ECOG, Eastern Cooperative Oncology Group; R/R, relapsed/refractory.

*Prior therapy data from one patient are missing.*

### TABLE 2. Response Rate and Duration of CR for First-Line Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Treated Once Daily With Tagraxofusp 12 μg/kg

| Outcome                        | Stages 1-3 (n = 29) | Stage 4 (n = 36) | Overall (n = 65) |
|--------------------------------|---------------------|------------------|------------------|
| **Response rate, No. (%)**     |                     |                  |                  |
| CR + CRc                       | 21 (72)             | 16 (44)          | 37 (57)          |
| ORR                            | 26 (90)             | 23 (64)          | 49 (75)          |
| Bridged to SCT                 | 13 (45)             | 8 (22)           | 21 (32)          |
| Bridged to SCT after CR + CRc  | 12 (57)             | 7 (44)           | 19 (51)          |
| **Median duration of CR + CRc, months (95% CI)** | NR (5.9 to NR)     | 4.4 (2.3 to NR) | 24.9 (3.8 to NR) |
| Probability at 6 months, %     | 70                  | 44               | 59               |
| Probability at 12 months, %    | 65                  | 36               | 53               |
| Probability at 18 months, %    | 65                  | 36               | 53               |
| Probability at 24 months, %    | 65                  | 36               | 53               |
| **Median duration of follow-up, months** | 39                 | 19               | 34               |
| **Median OS, months (95% CI)** | 25.8 (9.7 to 53.9) | 11.5 (6.8 to 19.1) | 15.8 (9.7 to 25.8) |
| Survival probability at 12 months, % | 62                  | 49               | 55               |
| Survival probability at 18 months, % | 59                  | 41               | 50               |
| Survival probability at 24 months, % | 52                  | 25               | 40               |

Abbreviations: CR, complete response; CRc, CR with residual skin abnormality not indicative of disease; NR, not reached; ORR, objective response rate; OS, overall survival; SCT, stem-cell transplant.
21-day cycle. Key eligibility criteria are presented in the Data Supplement. The primary efficacy end point was complete response (CR) + clinical CR (CRC: CR with residual skin abnormalities not indicative of the active disease).13,15

This study was approved by the institutional review board at each center; all patients provided written informed consent.

RESULTS

Eighty-nine patients (including 44 from the continued access cohort) were enrolled from 2014 to 2018 (Data Supplement); 84 patients (65 1L and 19 R/R) received TAG at a dose of 12 mg/kg once daily and were efficacy-evaluable. The median duration of follow-up was 34.0 months. Baseline demographics and clinical characteristics are summarized in Table 1.

For 1L patients with BPDCN, the objective response rate was 75% and the CR + CRC rate was 57% (95% CI, 44.0 to 69.2); the median time to, and duration of, CR + CRC was 39 (range, 14-131) days and 24.9 months (95% CI, 3.8 to not reached), respectively (Table 2 and Data Supplement). The median number of treatment cycles was four (range, 1-76), the overall response rate (ORR) was 75%, and the median time to response was 23 (range, 14-97) days. The median overall survival (OS) was 15.8 months (95% CI, 9.7 to 25.8; Data Supplement); survival probabilities are detailed in Table 2. The median number of doses in cycle 1 was four (range, 1-5); response rates did not appear to vary on the basis of the number of doses received in cycle 1 (Data Supplement). The median number of doses per cycle in cycles 2 was five (including patients who received 5 doses in cycle 1).

Overall, 51% of patients who achieved CR + CRC were bridged to SCT (Data Supplement; autologous SCT, n = 6; allogeneic SCT, n = 13). The median number of cycles before SCT was four (range, 2-8). Patient characteristics and efficacy for those who bridged to SCT are presented in the Data Supplement. Of patients who achieved CR + CRC and underwent transplant, the median OS was 38.4 months (range, 3.4-58.1; Data Supplement); the median follow-up post-SCT was 34 (range, 19-47) months, with 72% remaining in remission for ≥ 12 months post-SCT. The survival probability at 24 months was 66% (95% CI, 43 to 88). Four of 18 patients who achieved CR + CRC and were not transplanted had a prolonged duration of responses (> 6 months), two with responses lasting 27 and 52 months, respectively.

Twenty-one (70%) of 30 patients with baseline bone marrow (BM) disease achieved clearance of malignant disease; the median time to BM CR was 29 (range, 14-57) days. In total, 37% of patients who achieved CR + CRC and bridged to SCT had increased baseline BM blasts (range, 12%-94%).

For the 19 efficacy-evaluable R/R patients, the ORR was 58% (95% CI, 33.5 to 79.7), including one CR and two CRC. The median time to response was 29 (range, 21-82) days, and the median number of treatment cycles was two (range, 1-7). The median OS was 8.2 months (95% CI, 4.1 to 11.9), with a median follow-up of 33.5 months. One patient achieved disease remission and was bridged to allogeneic SCT.

Table 3 summarizes the most common any-grade and grade ≥ 3 AEs in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

### Table 3. Summary of Most Common Any-Grade and Grade ≥ 3 AEs in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

| AE                                      | Total (N = 89), No. (%) |
|-----------------------------------------|------------------------|
| AE leading to discontinuations          | 6 (7)                  |
| AE leading to dose interruption         | 61 (69)                |
| Weight increased                        | 24 (27)                |
| AST increased                           | 17 (19)                |
| ALT increased                           | 15 (17)                |
| Hypoalbuminemia                         | 14 (16)                |
| AEs of any grade that occurred in at least 20% of patients |                      |
| ALT increased                           | 57 (64)                |
| AST increased                           | 53 (60)                |
| Hypoalbuminemia                         | 45 (51)                |
| Fatigue                                 | 39 (44)                |
| Pyrexia                                 | 39 (44)                |
| Thrombocytopenia                        | 38 (43)                |
| Nausea                                  | 37 (42)                |
| Edema peripheral                        | 37 (42)                |
| Weight increased                        | 31 (35)                |
| Hyperglycemia                           | 27 (30)                |
| Chills                                  | 24 (27)                |
| Headache                                | 22 (25)                |
| Constipation                            | 22 (25)                |
| Anemia                                  | 21 (24)                |
| Hypotension                             | 21 (24)                |
| CLS                                     | 19 (21)                |
| Hypokalemia                             | 18 (20)                |
| Hypocalcemia                            | 18 (20)                |
| At least one grade ≥ 3 TEAE             | 75 (84)                |
| Thrombocytopenia                        | 29 (33)                |
| ALT increased                           | 28 (32)                |
| AST increased                           | 27 (30)                |

NOTE. This analysis includes three patients treated once daily with tagraxofusp 7 μg/kg. Events include preferred terms defined with the use of the Medical Dictionary of Regulatory Activities, version 19.0. Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLS, capillary leak syndrome; TEAE, treatment-emergent adverse event.
experienced any TEAE in cycle $\geq 5$. Myelosuppression was modest, reversible, and limited to the first one to two treatment cycles. There was no cumulative hematologic toxicity with continued TAG treatment. The incidence of TEAEs leading to TAG discontinuation was relatively low (7%) although dose interruptions were more common, with an incidence of 69%. The most frequent TEAEs leading to dose interruption are shown in Table 3. There were nine (10%) grade 5 events; four were deemed treatment related by the investigator (three capillary leak syndrome [CLS] and one myocardial infarction).

Eighteen (21%) patients treated at 12 mcg/kg had CLS (Data Supplement); most cases were nonsevere (grade 2, 67%) and resolved. All but one event occurred in cycle 1. The median time to CLS onset from therapy initiation was 6 (range, 3-51) days, and the duration of CLS ranged from 3-69 days (median: 6 days). Nine patients who experienced CLS continued TAG after CLS was resolved; no patients experienced a recurrence. CLS events were managed by holding additional TAG doses, administering intravenous albumin or steroids, and managing volume status. All patients who experienced CLS received concurrent albumin; eight received steroids.

**DISCUSSION**

This long-term analysis of the 0114 study demonstrates that TAG monotherapy resulted in substantial rates of ORR and durable CR + CRc in 1L patients, with a rapid time to onset. TAG led to major reductions in BM blasts, including in patients with baseline BM blasts up to 94%. Treatment enabled 51% of 1L patients who achieved remission to bridge to SCT; seven patients achieved a CR + CRc after a single cycle. Four of 18 patients who achieved a CR + CRc and were not transplanted had prolonged responses (> 6 months).

The response rate of 58% in R/R patients is notable given that little meaningful efficacy has been reported in this setting.3,16-18 The response was rapid, generally occurring after one to two cycles. TAG demonstrated a well-characterized and manageable safety profile. Most adverse events occurred during the first cycle and were transient, with no evidence of cumulative toxicity over multiple cycles; few led to treatment discontinuation. CLS, the most important identified risk, primarily occurred in cycle 1 and generally did not recur. CLS can be managed with the risk management and early intervention guidelines developed in this study12-15 (Data Supplement).

These data confirm the efficacy of TAG for the treatment of 1L patients with BPDCN and as a rational therapeutic option for patients with R/R disease. TAG may serve as a bridge to SCT in both populations or as induction/maintenance in patients not bridged to SCT. The longer treatment durations are an important benefit, as SCT may not be a viable path for all patients because of elderly age, comorbid conditions, lack of a donor match, or socio-economic factors.

**AFFILIATIONS**

1The University of Texas MD Anderson Cancer Center, Houston, TX
2H. Lee Moffitt Cancer Center, Tampa, FL
3City of Hope National Medical Center, Duarte, CA
4Roswell Park Comprehensive Cancer Center, Buffalo, NY
5Duke University Medical Center, Durham, NC
6The Ohio State University Comprehensive Cancer Center, Columbus, OH
7Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
8Stemline Therapeutics, New York, NY
9Tufts University School of Medicine, Boston, MA
10Dana-Farber Cancer Institute, Boston, MA

**CORRESPONDING AUTHOR**

Naveen Pemmaraju, MD, Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77030; e-mail: npemmaraju@mdanderson.org.

**PRIOR PRESENTATION**

Presented in part at the 26th Annual Virtual Congress of the European Hematology Association (abstr EP427), June 9-17, 2021.

**SUPPORT**

Supported by Stemline Therapeutics Inc, New York, NY. Stemline Therapeutics, a Menarini Group company, provided funding for this study and participated in the study design; data collection, analysis, and interpretation; and the development, review, and approval of this manuscript. Additional support was provided by The Leukemia & Lymphoma Society Therapy Acceleration Program.

**CLINICAL TRIAL INFORMATION**

NCT02113982

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.22.00034.

**DATA SHARING STATEMENT**

Data that underlie the results reported in a published article may be requested for products and the relevant indications that have been authorized by the regulatory authorities in Europe/the United States (or, if not, 2 years have elapsed since the study completion). Stemline, a member of the Menarini Group, will review requests individually to determine whether (1) the requests are legitimate and relevant and meet sound scientific research principles, (2) the requests are within the scope of the participants’ informed consent, and (3) the request is compliant with any applicable law and regulation and with any contractual relationship that Stemline and its affiliates and partners have in place with respect to the study and/or the relevant product. Prior to making data available, requestors will be required to agree in writing to certain obligations, including without limitation, compliance with applicable privacy and other laws and regulations. Proposals should be directed to
medicalinfo@stemline.com, and they will work toward removing IPD from clinicaltrial.gov as soon as technically feasible.

**AUTHOR CONTRIBUTIONS**

Conception and design: Naveen Pemmaraju, Kendra L. Sweet, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Hagop Kantarjian, Andrew A. Lane

Administrative support: Tariq I. Mughal

Provision of study materials or patients: Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Hagop Kantarjian

Collection and assembly of data: Naveen Pemmaraju, Kendra L. Sweet, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Tariq I. Mughal, Marina Konopleva

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**ACKNOWLEDGMENT**

We thank the patients and their families, as well as the participating study teams, for making this study possible. Editorial and medical writing assistance was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands and funding of this was supported by Stemline Therapeutics, Inc. The authors are fully responsible for all content and editorial decisions for this manuscript.

**REFERENCES**

1. Pagano L, Valentini CG, Pulsoni A, et al: Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study. Haematologica 98:239-246, 2013

2. Han L, Qiu P, Zeng Z, et al: Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A 87:346-356, 2015

3. Pagano L, Valentini CG, Grammatico S, et al: Blastic plasmacytoid dendritic cell neoplasm: Diagnostic criteria and therapeutic approaches. Br J Haematol 174:188-202, 2016

4. Taylor T, Haddadin M, Upadhyay VA, et al: Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood 134:679-687, 2019

5. Dietrich S, Andrilis M, Hegenbart U, et al: Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: Results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 17:1250-1254, 2011

6. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, et al: Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant 19:1006-1012, 2013

7. Frankel A, Liu JS, Rizzieri D, et al: Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 49:543-553, 2008

8. Fanny D, Frankel AE, Seilles E, et al: Preclinical studies of SL-401, a targeted therapy directed to the interleukin-3 receptor (IL3-R), in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Potent activity in BPDCN cell lines, primary tumor, and in an in vivo model. Blood 122:21, 2013 (supp; abstr 3942)

9. Frankel AE, Woo JH, Ahn C, et al: Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124:385-392, 2014

10. Alfayez M, Konopleva M, Pemmaraju N: Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther 20:115-123, 2020

11. Lee SS, McCue D, Pemmaraju N: Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther 20:543-550, 2020

12. Elzonris (tagraxofusp-erzs) injection [prescribing information]. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf

13. Jen EY, Gao X, Li L, et al: FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res 26:532-536, 2020

14. Elzonris [summary of product characteristics]. 2021. https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf

15. Pemmaraju N, Lane AA, Sweet KL, et al: Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm. N Engl J Med 380:1628-1637, 2019

16. Martín-Martín L, López A, Vídreas B, et al: Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6:19204-19216, 2015

17. Dalle S, Beylot-Barry M, Bagot M, et al: Blastic plasmacytoid dendritic cell neoplasm: Is transplantation the treatment of choice? Br J Dermatol 162:74-79, 2010

18. Beziat G, Ysebaert L: Tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN): A brief report on emerging data. Onco Targets Ther 13:5199-5205, 2020
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Naveen Pemmaraju
Employment: MD Anderson Cancer Center
Leadership: ASH, ASCO
Honoraria: Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer, Apteptitude Health, NeoPharm, CareDX
Consulting or Advisory Role: Blueprint Medicines, Pacylex, Immunogen, Bristol Myers Squibb, ClearView Healthcare Partners, Astellas Pharma, Protagonist Therapeutics, Triptych Health Partners, CTI BioPharma Corp
Research Funding: Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix/Thermo Fisher Scientific, Daiichi Sankyo, Plexoikon, MustangBio
Travel, Accommodations, Expenses: Stemline Therapeutics, Celgene, AbbVie, DAVA Oncology, MustangBio
Uncompensated Relationships: Dan’s House of Hope, Oncology Times
Anthony S. Stein
Speakers’ Bureau: Amgen
Eunice S. Wang
Consulting or Advisory Role: AbbVie, Pfizer, Jazz Pharmaceuticals, Astellas Pharma, Stemline Therapeutics, Kite/Gilead, PTC Therapeutics, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Novartis, Genentech, Takeda, Gilead Sciences, PharmaEssentia
Speakers’ Bureau: Stemline Therapeutics, Pfizer, DAVA Oncology, Kite, a Gilead Company, Astellas Pharma
David A. Rizziere
Consulting or Advisory Role: Novartis, Gilead Sciences, Sanofi, Pfizer, Seattle Genetics, Incyte, Millennium (I), Onyx (I), Kite, a Gilead Company, Celgene (I), Stemline Therapeutics, MustangBio, AbbVie, Jazz Pharmaceuticals
Speakers’ Bureau: Gilead Sciences, Incyte, Seattle Genetics, Celgene, Millennium (I), Stemline Therapeutics, Karyopharm Therapeutics (I), GlaxoSmithKline (I), MorphoSys, Kite, a Gilead Company, AbbVie
Research Funding: Asuragen (Inst), Genentech (Inst), Sanofi (Inst), Stemline Therapeutics (Inst), Takeda (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), Celator (Inst), AbbVie (Inst), MacroGenics (Inst), Ambit BioSciences (Inst), Astellas Pharma (Inst), KaloBios (Inst), Sells Life Sciences (Inst), Synops Pharmaceuticals (Inst), MedImmune (Inst), Cantex Pharmaceuticals (Inst), Arog (Inst), Astex Pharmaceuticals (Inst), Helsinn Healthcare (Inst), Agios (Inst), Toleron Pharmaceuticals (Inst), MEI Pharma (Inst), FORMA Therapeutics (Inst), Eureka Therapeutics (Inst), Nohia Therapeutics (Inst)
Expert Testimony: Celltrion
Other Relationship: Takeda (I)

Sumithira Vasu
Consulting or Advisory Role: Omeros, Johnson & Johnson
Research Funding: Sanofi (Inst)
Open Payments Link: https://openpaymentsdata.cms.gov/physician/725618
Todd L. Rosenblat
Honoraria: Astellas Pharma
Research Funding: Astex Pharmaceuticals, Celator
Christopher L. Brooks
Employment: Stemline Therapeutics
Leadership: Stemline Therapeutics

Honoraria: Amgen (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), AbbVie (Inst), Immunogen (Inst), Jazz Pharmaceuticals (Inst)
Consulting or Advisory Role: AbbVie
Research Funding: Amgen (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), AbbVie (Inst), Immunogen (Inst), Jazz Pharmaceuticals (Inst), Ascentage Pharma (Inst), Daiichi-Sankyo/Lilly (Inst)

Hagop Kantarjian
Honoraria: AbbVie, Amgen, Pfizer, Ascentage Pharma Group, Astellas Pharma, AstraZeneca/MedImmune, Ipsen, KAHR Medical, Novartis, Precision Biosciences, Shenzhen Target Rx, Taiho Pharmaceutical, Daiichi-Sankyo (Inst), Immunogen (Inst), Jazz Pharmaceuticals (Inst)
Consulting or Advisory Role: AbbVie
Research Funding: Amgen (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), AbbVie (Inst), Immunogen (Inst), Jazz Pharmaceuticals (Inst), Ascentage Pharma (Inst), Daiichi-Sankyo/Lilly (Inst)

Marina Konopleva
Honoraria: AbbVie, Genentech, Roche, Amgen, Stemline Therapeutics, KisoJi Biotechnology, Forty Seven
Consulting or Advisory Role: AbbVie, Genentech/Roche, Stemline Therapeutics, Amgen, Forty Seven, KisoJi Biotechnology, Roche, Janssen
Research Funding: AbbVie (Inst), Genentech (Inst), Roche (Inst), Lilly (Inst), Collectis (Inst), Celthera Biosciences (Inst), Ablynx (Inst), Agios (Inst), Ascentage Pharma (Inst), AstraZeneca (Inst), Sanofi, Forty Seven (Inst)
Patents, Royalties, Other Intellectual Property: Novartis—PENDING, Eli Lilly—Research Funding; Issued/Licensed, Reata Pharmaceuticals—Research Funding (Issued, Licensed, Royalties), Reata Pharmaceuticals—Research Funding (Issued, Licensed, Royalties)

Andrew A. Lane
Consulting or Advisory Role: Stemline Therapeutics, Qiagen
Research Funding: Stemline Therapeutics, AbbVie
Patents, Royalties, Other Intellectual Property: Methods for determining and treating toxin-conjugate resistance in cancer (Inst)

No other potential conflicts of interest were reported.